Skip to content
ChickenStockChickenStock
ResearchKNSA
Kiniksa Pharmaceuticals Internation logo

Kiniksa Pharmaceuticals Internation (KNSA) stock

NASDAQ

$95.12+0.94%(+0.89)

As of the Nov 17, 2026 close (U.S. Eastern)

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

68.57x

P/B

10.53x

P/S

7.90x

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue increased 58.0% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Oct 27, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

40 SEC filings
  • Paolini John F.CHIEF MEDICAL OFFICER · Nov 13, 2026Option exercise44,126 shares · $488K
    Avg. price $11.069
    Show 5 price lots
    • 29,670 shares × $10.36$307K
    • 4,994 shares × $11.1$55K
    • 3,723 shares × $11.97$45K
    • 3,144 shares × $12.97$41K
    • 2,595 shares × $15.52$40K
  • Megna Michael RCHIEF ACCOUNTING OFFICER · Nov 9, 2026Open-market sale11,280 shares · $1.1M
    Avg. price $98.5412,697 shares held after
  • Megna Michael RCHIEF ACCOUNTING OFFICER · Nov 9, 2026Option exercise11,280 shares · $200K
    Avg. price $17.7623,977 shares held after
  • Patel Sanj KCHAIRMAN & CEO · Nov 4, 2026Open-market sale151,300 shares · $14.3M
    Avg. price $94.7143
    Show 5 price lots
    • 81,742 shares × $94.2$7.7M
    • 29,845 shares × $95.48$2.8M
    • 26,918 shares × $96.05$2.6M
    • 11,335 shares × $93.54$1.1M
    • 1,460 shares × $92.35$135K
  • Patel Sanj KCHAIRMAN & CEO · Nov 4, 2026Option exercise145,763 shares · $2.6M
    Avg. price $17.92925,800 shares held after
  • Patel Sanj KCHAIRMAN & CEO · Nov 3, 2026Open-market sale220,170 shares · $20.5M
    Avg. price $93.2709
    Show 4 price lots
    • 145,708 shares × $93.53$13.6M
    • 68,664 shares × $92.7$6.4M
    • 4,584 shares × $94.25$432K
    • 1,214 shares × $90.77$110K
  • Patel Sanj KCHAIRMAN & CEO · Nov 3, 2026Option exercise130,326 shares · $1.5M
    Avg. price $11.7062
    Show 2 price lots
    • 89,089 shares × $8.83$787K
    • 41,237 shares × $17.92$739K
  • Patel Sanj KCHAIRMAN & CEO · Nov 2, 2026Open-market sale89,433 shares · $8.2M
    Avg. price $91.8575
    Show 4 price lots
    • 38,364 shares × $91.03$3.5M
    • 26,781 shares × $93.06$2.5M
    • 24,188 shares × $91.83$2.2M
    • 100 shares × $93.97$9K
  • Paolini John F.CHIEF MEDICAL OFFICER · Nov 2, 2026Open-market sale18,413 shares · $1.7M
    Avg. price $93.3944
    Show 3 price lots
    • 16,810 shares × $93.42$1.6M
    • 899 shares × $92.37$83K
    • 704 shares × $94.09$66K
  • Ragosa MarkCHIEF FINANCIAL OFFICER · Nov 2, 2026Open-market sale36,783 shares · $3.4M
    Avg. price $92.1615
    Show 4 price lots
    • 14,027 shares × $91.4$1.3M
    • 12,034 shares × $93.13$1.1M
    • 10,502 shares × $92.03$966K
    • 220 shares × $94.01$21K
  • Moat RossCHIEF OPERATING OFFICER · Nov 2, 2026Open-market sale27,977 shares · $2.6M
    Avg. price $92.3635
    Show 4 price lots
    • 11,642 shares × $93.15$1.1M
    • 8,932 shares × $92.05$822K
    • 6,681 shares × $91.23$610K
    • 722 shares × $94.05$68K
  • Patel Sanj KCHAIRMAN & CEO · Nov 2, 2026Option exercise53,381 shares · $471K
    Avg. price $8.83959,314 shares held after
  • Moat RossCHIEF OPERATING OFFICER · Nov 2, 2026Option exercise21,714 shares · $438K
    Avg. price $20.1619
    Show 2 price lots
    • 12,302 shares × $21.77$268K
    • 9,412 shares × $18.06$170K
  • Paolini John F.CHIEF MEDICAL OFFICER · Nov 2, 2026Option exercise18,413 shares · $414K
    Avg. price $22.4809
    Show 2 price lots
    • 11,958 shares × $17.92$214K
    • 6,455 shares × $30.93$200K
  • Ragosa MarkCHIEF FINANCIAL OFFICER · Nov 2, 2026Option exercise9,636 shares · $171K
    Avg. price $17.7657,637 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Kiniksa Pharmaceuticals Internation (KNSA) stock information

NASDAQ

Kiniksa Pharmaceuticals Internation (KNSA) is listed on NASDAQ. Its market capitalization is about $7.5B. On trailing-twelve-month earnings the P/E ratio is 68.57, and the P/B ratio is 10.53. Return on equity is 15.4%. These figures are computed in-house from official filings and are reference information only.

Kiniksa Pharmaceuticals Internation — frequently asked questions

What is the P/E ratio of Kiniksa Pharmaceuticals Internation (KNSA)?
On a trailing-twelve-month basis, KNSA trades at a P/E ratio of 68.57. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Kiniksa Pharmaceuticals Internation?
KNSA has a market capitalization of about $7.5B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.